Source 1review2025MED
Toolkit/miRNA-based regulation
miRNA-based regulation
Taxonomy: Mechanism Branch / Component. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Future directions in ocular gene therapy include the development of precision genome editing techniques, such as prime editing, miRNA-based regulation, and combinatorial approaches integrating gene therapy with stem cell transplantation or neuroprotective agents.
Usefulness & Problems
Why this is useful
miRNA-based regulation is presented as a future direction for ocular gene therapy. It represents a regulatory RNA-oriented strategy rather than a conventional augmentation-only approach.; future ocular gene regulation strategies
Source:
miRNA-based regulation is presented as a future direction for ocular gene therapy. It represents a regulatory RNA-oriented strategy rather than a conventional augmentation-only approach.
Source:
future ocular gene regulation strategies
Problem solved
It expands the toolkit for controlling disease-relevant gene expression in posterior segment eye disease.; expanding precision regulatory approaches in ocular gene therapy
Source:
It expands the toolkit for controlling disease-relevant gene expression in posterior segment eye disease.
Source:
expanding precision regulatory approaches in ocular gene therapy
Problem links
expanding precision regulatory approaches in ocular gene therapy
LiteratureIt expands the toolkit for controlling disease-relevant gene expression in posterior segment eye disease.
Source:
It expands the toolkit for controlling disease-relevant gene expression in posterior segment eye disease.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Component: A low-level RNA part used inside a larger architecture that realizes a mechanism.
Mechanisms
rna-based gene expression regulationTechniques
No technique tags yet.
Target processes
editingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationimplementation constraint: payload burdenoperating role: regulator
requires ocular delivery and disease-relevant regulatory design
The abstract does not specify which miRNAs, targets, or delivery systems are involved. It therefore supports only a high-level extraction.; abstract does not specify implementation format, targets, or validation status
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
FDA approval of voretigene neparvovec validated the clinical viability of ocular gene therapy.
Dual AAV vectors, lipid nanoparticles, and novel biomaterials have enhanced the efficiency and specificity of gene delivery to the retina.
Future ocular gene therapy development is expected to include prime editing, miRNA-based regulation, and combinatorial approaches with stem cell transplantation or neuroprotective agents.
Gene augmentation, gene editing, RNA-based therapies, and optogenetics have shown significant progress in preclinical studies and clinical trials across posterior segment eye disease subtypes.
Approval Evidence
1 source1 linked approval claimfirst-pass slug mirna-based-regulation
Future directions in ocular gene therapy include the development of precision genome editing techniques, such as prime editing, miRNA-based regulation, and combinatorial approaches integrating gene therapy with stem cell transplantation or neuroprotective agents.
Source:
future directionsupports
Future ocular gene therapy development is expected to include prime editing, miRNA-based regulation, and combinatorial approaches with stem cell transplantation or neuroprotective agents.
Source:
Comparisons
Source-stated alternatives
The review mentions prime editing and combinatorial gene-therapy approaches as adjacent future strategies.
Source:
The review mentions prime editing and combinatorial gene-therapy approaches as adjacent future strategies.
Source-backed strengths
highlighted as a future direction in the field
Source:
highlighted as a future direction in the field
Compared with prime-editing
The review mentions prime editing and combinatorial gene-therapy approaches as adjacent future strategies.
Shared frame: source-stated alternative in extracted literature
Strengths here: highlighted as a future direction in the field.
Relative tradeoffs: abstract does not specify implementation format, targets, or validation status.
Source:
The review mentions prime editing and combinatorial gene-therapy approaches as adjacent future strategies.
Ranked Citations
- 1.